Member Info for Fruitsnveg

"The purpose of this Prior Information Notice is to assess and understand the COVID-19 antivirals market by gathering information through market engagement and to gain a more detailed understanding of the market."
I don't mean to be glib (or maybe I do), but couldn't they have gained "a more detailed understanding of the market" by getting half a dozen op pulmonologists or Respiratory boffins into a room with a white board, marker and some nice cream teas, a couple of months, or even a year ago? Even in preparation?? We are 2 years + into this and only now are they wishing to "gain a more detailed understanding of the market"?! Utterly baffling.

I'll raise your LOL and double it Matml74

"Tender Value: 0 - £1." Lol, Lol.

Great find Owl.

Sept 2020 - Prof Wilko and experience of a patient who took SNG001 during trials.
https://www.youtube.com/watch?v=TbiqKsbkR_I

Mr. Costs, Professor Wilko declares his conflicts of interests. He consistently reports grants and personal fees in all publications he has contributed articles to, e.g. "T.M.A. Wilkinson reports personal fees and other from MMH, grants and personal fees from GSK, AstraZeneca and Synairgen, and personal fees from Boehringer Ingelheim, outside the submitted work." It is acceptable, legal and ethical to be invested in something AS LONG as those interests are publicly declared, a point our shyster PM and cabal of self-serving ministers have yet to grasp. Unfortunately, the same level of transparency has not been adopted by another "doctor" Campbell (along with others) on the internet who IMO gets far too much airtime on this BB. ..

Patagucci,
My understanding, but please correct me if I'm wrong on it, is this - there may be deaths (triallists are sick humans after all) but it will be up to the investigators to ascertain cause of death. If deaths occur they have to be investigated rigorously. It may, or may not, be the caused by the drug trialled.

Mr Costs,
THe SP refkects the risk investors are currently running. Any trial can confound and surprise, no matter the history of the drug. We've seen its already with Activ2P2 triallists. Nothing is a given. And Yes, I believe in SNG001, especially after P2 data and Activ2P2 amongst so many other positive signs and science over the year. But until data (or news?) comes in, personally I don't see the SP moving a whole lot, other than to oblige the usual deramping/MM/order-filling shenanigans. I think it is what it is for the final weeks.

If you can't breath it in, and you can't ingest it, you're much less likey to catch it and transmit it.

I meant...

No joke. The vaccine and booster don't stop you getting it Mr. Costs, not the more recent Delta variant.
Add mask, SD, handwashing for more protection.

If you can't breath i, and you can't ingest it, you're much less likey to catch it and transmit it.
Hope your FIL well soon.

Interesting figs Gunto, I agree, they will want a tranche if the drug shows promise in their trial (otherwise what was the point of their investment in trialling it?).

Great catch Andy123, my apologies for mixing you both up!

All good points ANdybe4 and I share your sense of worry on the deteriorating geo-politics. THese problems are for the most part solveable, one can only hope they get solved.

Andyb4
"People might opt not to get their boosters and instead take their chances, knowing that SNG001 is there in the hospital should they need it." From a public health perspective this would be completley untenable. If a % of those who refused he jab became infected and ended up in hospital, they won't even make it to the hospital doors because hospitals won't cope with that influx. Many are already, as we know, unable to even give basic cancer care right now. The whole point of vaccinations is to save an already overstretched public health service from being brought to it's knees. What you are suggesting is a good way to level it to the ground. SO i don't think the government will opt for this model, they have thus far resisted it.

On your 2nd point, I don't see SNG001 as a threat to Pfizers vaccine. RM has stated many times that even the vaccinated end up in hospital. What then? A Pfizer vaccine isn't going to cut it. THey need something else, something like SNG001.

To your other point "Pfizer demands the monopoly and knows that SNG001 is a threat to them, so they bid a higher price to buy Synairgen out" There are competition laws that prevent such a scenario (if what you menat was buying a competitor in order to 'bury' it's product). If on the other hand you envisage a Pfizer TO so they can make money out of selling a Pfizer labelled SNG001, then I'd expect top dollar from them (£50 for arguments sake) if that's what it's worth to them than that's the price you pay to acheive monopoly, right? All the above are hypotethetical of course just to illustrate, but IMO Synairgen is persuing, as they've always showed preference for, licencing deals, not a TO.

I understand your thinking regarding your personal predicament though. Personally, I remain hopeful of a day when genetic testing is available to screen the population for the weakness that we now know leads to more sever Covid. AT that point, one could more safely ditch the vaccines if one knew they were'nt genetically predisposed to worse outcomes (ie severe disease/death) and at that point choose a more natural route of building up immunity via real infection. Until that day comes (and I hope it will be soon) I wil rely on the boosters.

https://www.theguardian.com/world/2021/nov/15/bird-flu-europe-asia
"It is attracting the attention too of epidemiologists as the virus can be transmitted to humans. China has reported 21 human infections with the H5N6 subtype of avian influenza so far this year, more than in the whole of 2020."

It looks like scientists will be busy for years developing treatments and vaccines for all manner of flu viruses, etc.

https://www.theguardian.com/world/2021/nov/15/uk-vaccine-advisers-set-to-approve-covid-booster-jabs-for-under-50s

Welcome back Doc BTW. Was it RM's panel appearance that brought to back, or something else? It must be busy at work these days, no?

I think it's what they call a Sailor's tan Doc, or perhaps a far-flung business trip...
The panel was about Lessons Learned w/in industry in this pandemic that can be carried fwd to the next; it was not an investor road-show, or beauty parade for bankers.
Whilst the global scope of our P3 is interesting to us, he has already commented in previous webinars (on the success of said P3 trial). Worth noting that RM was the only panellist awaiting official trial results and possibly? in negotiation with various parties, so as you will appreciate, often the less said at this stage about Synairgen 'specifics', the better. We know RM likes to keep his cards close to his chest.

Brand,
We've had them all for 18 months, they never were true, so take that as you're baseline. Entertaining, but nothing more than hot gaseous twaddle;
Nobby's 'late night' calls with RM (lol)
Org's emails from Consillium Kim (lol, lol)
Dan's NYC Activ 'contact' (lol, lol, lol)
Etc
I could go on, but I think you get the picture.

It's an industry specific event focused on lessons learnt, I don't think we can expect the panellists to wax lyrical too much on their own situations (although I admit that would have been nice for us PI's). Also I think the adjudicator was lacklustre, he could have funnelled the panel a bit better, they were all lukewarm. That's the problem with lessons learned - they are often much more frank behind closed doors!

Interesting point on the threat of cheap Chinese drugs/biologics. RM commented that patents are protecting innovators, there's enough slices of the pie to go around and it's a natural part of the lifecycle.

Quality over quantity. He'll make a point if it's worth making.